Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Interest & Investment Income (2023 - 2025)

Aclaris Therapeutics (ACRS) has 3 years of Interest & Investment Income data on record, last reported at $1.6 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 22.34% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $7.6 million, down 3.97%, while the annual FY2025 figure was $7.6 million, 3.97% down from the prior year.
  • Interest & Investment Income reached $1.6 million in Q4 2025 per ACRS's latest filing, down from $1.8 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $2.3 million in Q3 2023 and bottomed at $1.6 million in Q4 2025.
  • Average Interest & Investment Income over 3 years is $2.0 million, with a median of $2.0 million recorded in 2024.
  • The widest YoY moves for Interest & Investment Income: up 8.84% in 2025, down 22.34% in 2025.
  • A 3-year view of Interest & Investment Income shows it stood at $2.3 million in 2023, then decreased by 9.15% to $2.1 million in 2024, then fell by 22.34% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $1.6 million in Q4 2025, $1.8 million in Q3 2025, and $2.0 million in Q2 2025.